NKG2-A Inhibitors
The chemical class of NKG2-A Inhibitors would encompass a range of compounds that indirectly influence the activity of the NKG2-A receptor on natural killer cells. These compounds achieve this by modulating the expression of HLA-E, the ligand for NKG2-A, or by interfering with the intracellular signaling cascades that follow NKG2-A engagement.
Brefeldin A, MG132, and Cyclosporin A are examples of compounds that can affect the expression of HLA-E on the surface of cells. Brefeldin A disrupts the protein transport machinery, which is essential for the presentation of HLA-E molecules on the cell surface. MG132 inhibits the proteasome, which can lead to the accumulation of HLA-E molecules inside the cell, affecting their availability to interact with NKG2-A. Cyclosporin A has immunosuppressive properties and can downregulate the expression of HLA-E, thus potentially decreasing NKG2-A engagement. The remaining compounds listed, such as LY294002, PP2, Chelerythrine, PD98059, SB203580, ZM 447439, Dasatinib, U0126, and Rapamycin, act on various intracellular signaling pathways. These inhibitors target kinases like PI3K, Src family kinases, protein kinase C, MEK, p38 MAP kinase, Aurora kinase, and mTOR. By modulating these kinases, the compounds can influence the signaling pathways that might be activated following NKG2-A engagement with its ligand, thus indirectly inhibiting the function of NKG2-A.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein transport in eukaryotic cells, which can decrease the cell surface expression of HLA-E, thus affecting NKG2-A engagement. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can lead to increased expression of HLA-E, potentially altering NKG2-A signaling indirectly. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that can downregulate HLA-E expression, thereby modifying the interaction with NKG2-A. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, which can affect downstream signaling of NKG2-A upon ligand binding. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Inhibits Src family kinases, which are involved in downstream signaling of receptor-ligand engagements, including potentially NKG2-A. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
A protein kinase C inhibitor, which can modulate signaling pathways within NK cells, possibly affecting NKG2-A signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, which can disrupt MAPK/ERK pathway signaling downstream of various receptors, including potentially NKG2-A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor, which can affect the signaling pathway that could be involved in the NKG2-A signaling cascade. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor, which may interfere with cell division and could indirectly influence the function of NKG2-A by affecting NK cell proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor, which can affect the activation state of various receptors on NK cells, potentially including NKG2-A. | ||||||